Home TMU FAQ Sitemap
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Indication
Institution
Department
Principal Investigator
Protocol Title
TMU-JIRB No. Protocol Title Indication Institution Department Principal Investigator Contact
N202407039 BI 690517合併恩排糖的心臟與腎臟保護研究：醛固酮合成酶抑制劑BI 690517合併恩排糖治療慢性腎臟病患者的多中心、國際、隨機、雙盲、安慰劑對照臨床試驗 慢性腎臟病 WFH 腎內科

鄭仲益

 02-29307930分機2550
N202206023 一項在罹患第二型糖尿病和慢性腎病的受試者中，探討腎臟自體細胞療法 (REACT) 的第三期隨機對照試驗 慢性腎臟病 WFH 腎內科

鄭仲益 

 0928692458
N202302038 一項第三期、多中心、隨機分配、雙盲、平行分組、安慰劑對照試驗，旨在評估 Tozorakimab (MEDI3506) 用於因病毒性肺部感染住院且需要補充氧氣的患者之療效及安全性 (TILIA) 病毒性肺部感染 WFH 感染科

歐聰億

 02-29307930分機2552
N201810016 A Phase III, Double-blind, Placebo controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer (AEGEAN) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee 02-6620-2589
N201903127 A Phase 1/1b Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants with Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee 02-6620-2589
N201905120 A phase III, open-label, randomized study of osimertinib with or without platinum plus pemetrexed chemotherapy, as first-line treatment in patients with epidermal growth factor receptor (EGFR) mutation-positive, locally advanced or metastatic non-small cell lung cancer (FLAURA2) Lung Cancer SHH Pulmonary Medicine Po-Hao Feng 02-6620-2589
N201912030 A Phase 3, Randomized, Doubleblind Study of Neoadjuvant Chemotherapy plus Nivolumab versus Neoadjuvant Chemothera py plus Placebo, followed by Surgical Resection and Adjuvant Treatment with Nivolumab o r Placebo for Participants with Resectable Stage II-IIIB Non-small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee 02-6620-2589
N202004125 A Phase III, Randomised, Controlled, Multi-centre, 3-Arm Study of Neoadjuvant Osimertinib as Monotherapy or in Combination with Chemotherapy versus Standard of Care Chemotherapy Alone for the Treatment of Patients with Epidermal Growth Factor Receptor Mutation Positive, Resectable Non-small Cell Lung Cancer (NeoADAURA) Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee 02-6620-2589
N202005083 A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee 02-6620-2589
N202005083 A Phase 2 Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination with AB122, and AB154 in Combination with AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer Lung Cancer SHH Pulmonary Medicine Kang-Yun Lee 02-6620-2589
1 2 7 8 9 10 11 12 13 14 15 16 / 16

TOP